A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
The agency’s stated goal for tweaking the ASP-based reimbursement formula is to learn whether it gives physicians the incentive to prescribe the most expensive treatments available.